These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 34618040

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H, Lai L, Wu B.
    Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.
    Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Hida T, Seto T, Horinouchi H, Maemondo M, Takeda M, Hotta K, Hirai F, Kim YH, Matsumoto S, Ito M, Ayukawa K, Tokushige K, Yonemura M, Mitsudomi T, Nishio M.
    Cancer Sci; 2018 Sep; 109(9):2863-2872. PubMed ID: 29959809
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M, Shao T, Shao H, Zhou C, Tang W.
    BMC Cancer; 2024 Feb 08; 24(1):186. PubMed ID: 38331773
    [Abstract] [Full Text] [Related]

  • 16. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, Ozaki Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Shio Y, Suzuki H.
    Thorac Cancer; 2021 Aug 08; 12(15):2225-2228. PubMed ID: 34159737
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Morcos PN, Nueesch E, Jaminion F, Guerini E, Hsu JC, Bordogna W, Balas B, Mercier F.
    Cancer Chemother Pharmacol; 2018 Jul 08; 82(1):129-138. PubMed ID: 29748847
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.